- Kennedy Urges Senate to Vote on CLARITY Act, Citing Years of Crypto Debate
- Disney (DIS.US) is up 2% pre-market as Q3 profits exceed expectations.
- ADVANCED MICRO DEVICES : MIZUHO CUTS TARGET PRICE TO $580 FROM $625
- Disney FY26 Q3 net income attributable to Disney drops 50% to $2.64 billion; revenue rises 7% to $25.25 billion
- Webuild signs EUR 2.7 billion contract for Ontario Line tunnel, stations in Toronto
- UBS lifts LEG Immobilien voting stake to 3.22% from 3.11%
- Thomson Reuters Q2 IFRS diluted EPS rises 48% to USD 1.02; revenue climbs 9% to USD 1.95 billion
- Delek Logistics Q2 FY26 net income drops to $28.9 million; adjusted EBITDA climbs to $143.5 million
- Investment banks claim 4000 is the bottom, multiple factors indicate structural opportunities in gold
- AMETEK : MIZUHO RAISES TARGET PRICE TO $285 FROM $270
- ADVANCED MICRO DEVICES, INC. : WELLS FARGO RAISES TARGET PRICE TO $700 FROM $615
- ARISTA NETWORKS, INC. : WELLS FARGO RAISES TARGET PRICE TO $255 FROM $200
- TOAST, INC. <TOST.N>: WELLS FARGO RAISES TARGET PRICE TO $40 FROM $36
- FIDELITY NATIONAL INFORMATION SERVICES, INC. <FIS.N>: WELLS FARGO CUTS TARGET PRICE TO $58 FROM $67
- SPACE EXPLORATION TECHNOLOGIES CORP. <SPCX.O>: WELLS FARGO CUTS TARGET PRICE TO $215 FROM $230
- BOOKING HOLDINGS INC. <BKNG.O>: WELLS FARGO RAISES TARGET PRICE TO $220 FROM $214
- COMPASS, INC. <COMP.N>: WELLS FARGO RAISES TARGET PRICE TO $13 FROM $12
- CENTURI HOLDINGS, INC. <CTRI.N>: WELLS FARGO CUTS TARGET PRICE TO $29 FROM $37
- WESTLAKE CORP. <WLK.N>: WELLS FARGO CUTS TARGET PRICE TO $89 FROM $110
- BALL CORPORATION <BALL.N>: WELLS FARGO RAISES TARGET PRICE TO $72 FROM $71
- GRAPHIC PACKAGING HOLDING COMPANY <GPK.N>: WELLS FARGO RAISES TARGET PRICE TO $10 FROM $9
- KNIFE RIVER CORPORATION <KNF.N>: WELLS FARGO CUTS TARGET PRICE TO $73 FROM $81
- LUMEN TECHNOLOGIES, INC. <LUMN.N>: WELLS FARGO CUTS TARGET PRICE TO $7.5 FROM $9
- SPYRE THERAPEUTICS, INC. <SYRE.O>: WELLS FARGO RAISES TARGET PRICE TO $115 FROM $90
- UL SOLUTIONS INC. <ULS.N>: WELLS FARGO CUTS TARGET PRICE TO $104 FROM $120
- GARTNER, INC. <IT.N>: WELLS FARGO RAISES TARGET PRICE TO $150 FROM $120
- LEMAITRE VASCULAR, INC. <LMAT.O>: WELLS FARGO CUTS TARGET PRICE TO $94 FROM $104
- BIO-RAD LABORATORIES, INC. <BIO.N>: WELLS FARGO RAISES TARGET PRICE TO $330 FROM $310
- WATERS CORP. <WAT.N>: WELLS FARGO RAISES TARGET PRICE TO $400 FROM $370
- ULTRAGENYX PHARMACEUTICAL INC. <RARE.O>: WELLS FARGO CUTS TARGET PRICE TO $45 FROM $47
- HINGE HEALTH, INC. <HNGE.N>: WELLS FARGO RAISES TARGET PRICE TO $103 FROM $90
- MARATHON PETROLEUM CORPORATION <MPC.N>: WELLS FARGO RAISES TARGET PRICE TO $359 FROM $344
- MPLX LP <MPLX.N>: WELLS FARGO RAISES TARGET PRICE TO $63 FROM $61
- THE WILLIAMS COMPANIES, INC. <WMB.N>: WELLS FARGO RAISES TARGET PRICE TO $90 FROM $89
- ANGEL OAK MORTGAGE REIT, INC. : WELLS FARGO CUTS TARGET PRICE TO $10 FROM $11
- CLAROS MORTGAGE TRUST, INC. <CMTG.N>: WELLS FARGO CUTS TARGET PRICE TO $1.75 FROM $2.5
- NEW MOUNTAIN FINANCE CORP. <NMFC.O>: WELLS FARGO CUTS TARGET PRICE TO $7.5 FROM $8
- AMGEN INC. : WELLS FARGO RAISES TARGET PRICE TO $400 FROM $390
- DIAMONDBACK ENERGY, INC. <FANG.O>: WELLS FARGO RAISES TARGET PRICE TO $263 FROM $262
- SUNOCO LP <SUN.N>: WELLS FARGO RAISES TARGET PRICE TO $82 FROM $77
- DORMAN PRODUCTS, INC. <DORM.O>: WELLS FARGO RAISES TARGET PRICE TO $160 FROM $155
- WAYFAIR, INC. <W.N>: WELLS FARGO RAISES TARGET PRICE TO $130 FROM $100
- VIKING HOLDINGS LTD. <VIK.N>: WELLS FARGO RAISES TARGET PRICE TO $128 FROM $109
- RED ROCK RESORTS, INC. <RRR.O>: WELLS FARGO RAISES TARGET PRICE TO $77 FROM $75
- NEW JERSEY RESOURCES CORPORATION <NJR.N>: WELLS FARGO CUTS TARGET PRICE TO $61 FROM $63
- BeiGene (BGNE.US) announced that global total revenue for the second quarter of 2026 was $1.705 billion, representing a 30% year-on-year increase. GAAP net profit was $237 million, compared to net profit of $94.32 million in the same period last year. GAAP diluted earnings per ADS were $2.05, compared to $0.84 in the same period last year. Global sales of Baizeze reached $1.2 billion, up 31% year-on-year. The company raised its full-year 2026 total revenue guidance to $6.6 billion to $6.8 billi
- FTC Solar Q2 FY26 net loss widens to $27.12 million; revenue rises 30.8% to $26.2 million y/y
- NCR Voyix Q2 FY26 net loss narrows to $1 million; revenue drops 21% to $523 million
- Delek Logistics declares quarterly cash distribution of $1.135 per unit
- PARAMOUNT SKYDANCE CORP : MOFFETTNATHANSON CUTS TARGET PRICE BY $3 TO $11
- BRIEF-Disney Q3 Adjusted EPS USD 2.06 Vs. IBES Estimate USD 1.86
- IA FINANCIAL CORPORATION INC <IAG.TO>: TD COWEN RAISES TARGET PRICE TO C$218 FROM C$214
- Bloomin' Brands Q2 FY26 diluted EPS rises 27.59% to $0.37; revenue increases 1.3% to $1.02 billion
- Recursion Q2 net loss narrows to $131.01 million; revenue drops to $7.67 million
- EVgo partners with Tesla to deploy V4 Superchargers across US metro network
- Discovery Mining reports high-grade drill intercepts at Dome project, resource update set for late 2026
- Compass Pathways Q2 FY26 net loss widens to $253.8 million
- BRIEF-BorgWarner Q2 Adjusted EPS USD 1.42 Vs. IBES Estimate USD 1.28
- BRIEF-Zimmer Biomet Q2 Adjusted EPS USD 2.07 Vs. IBES Estimate USD 2.01
- BRIEF-CVS Q2 Adjusted EPS USD 2.58 Vs. IBES Estimate USD 1.85
- BRIEF-Kennametal Q4 EPS USD 2.91
- BRIEF-FTC Solar Q2 Adjusted EPS USD -0.76
- BRIEF-NiSource Q2 Net Income USD 45.5 Million
- BRIEF-Delek US Holdings Q2 Adjusted EPS USD 5.48
- BRIEF-UTZ Brands Q2 Adjusted EPS USD 0.19 Vs. IBES Estimate USD 0.2
- BRIEF-Dynatrace Q1 Adjusted EPS USD 0.48 Vs. IBES Estimate USD 0.45
- BRIEF-Cencora Q3 Adjusted EPS USD 4.48 Vs. IBES Estimate USD 4.35
- BRIEF-Delek Logistics Partners Q2 Revenue USD 384.76 Million Vs. IBES Estimate USD 293.6 Million
- BRIEF-Choice Hotels International Inc Q2 EPS USD 1.41
- BRIEF-Freshpet Q2 Sales USD 305.6 Million Vs. IBES Estimate USD 292.2 Million
- BRIEF-NCR Voyix Q2 Adjusted EPS USD 0.17 Vs. IBES Estimate USD 0.15
- BRIEF-Bloomin' Brands Q2 Adjusted EPS USD 0.39 Vs. IBES Estimate USD 0.29
- BRIEF-Recursion Pharmaceuticals Q2 Operating Revenue USD 7.303 Million Vs. IBES Estimate USD 11.9 Million
- BRIEF-United Therapeutics Q2 Revenue USD 783.3 Million Vs. IBES Estimate USD 805.6 Million
- Choice Hotels Intl 2Q Rev $440.8M >CHH
- Choice Hotels Intl 2Q Net $64.3M >CHH
- Delek Logistics Partners 2Q Rev $384.8M >DKL
- PARAMOUNT SKYDANCE CORP : TD COWEN CUTS TARGET PRICE TO $8 FROM $13
- Cabral Gold appoints Elton Pereira as VP Exploration
- Bloomin' Brands 2Q Rev $1.02B >BLMN
- Choice Hotels Intl 2Q EPS $1.41 >CHH
- United Therapeutics 2Q Net $333M >UTHR
- Utz Brands 2Q Loss/Shr 11c >UTZ
- Utz Brands 2Q Adj EPS 19c >UTZ
- Utz Brands 2Q Sales $371.8M >UTZ
- Kennametal 4Q Net $227M >KMT
- Kennametal 4Q Sales $736.6M >KMT
- Zimmer Biomet Holdings 2Q Net $198.3M >ZBH
- Zimmer Biomet Holdings 2Q Sales $2.18B >ZBH
- Bloomin' Brands 2Q Net $31.3M >BLMN
- Freshpet 2Q EPS 39c >FRPT
- CVS Health 2Q EPS $2.31 >CVS
- CVS Health 2Q Front Store Same-Store Sales Up 1% >CVS
- Delek US 2Q Rev $4.09B >DK
- Delek US 2Q Adj EPS $5.48 >DK
- Delek Logistics Partners 2Q EBITDA $120M >DKL
- Recursion Pharmaceuticals 2Q Rev $7.67M >RXRX
- Elanco Animal Health 2Q Net $54M >ELAN
- Elanco Animal Health 2Q Rev $1.37B >ELAN
- Elanco Animal Health Sees 3Q Rev $1.2B-$1.22B >ELAN
